EFFECT OF BISPHOSPHONATE THERAPY ON SERUM OSTEOPROTEGERIN LEVELS IN PATIENTS WITH POSTMENOPAUSAL OSTEOPOROSIS

被引：0
|
作者：
Kang, Moo-Il [1 ]
Kim, Ghi-Su [2 ]
Lim, Seung-Kil [3 ]
Baek, Ki-Hyun [1 ]
Tae, Hyun-Jung [1 ]
Lee, Kwang-Woo [1 ]
机构：
[1] Catholic Univ Korea, Coll Med, Seoul, South Korea
[2] Univ Ulsan, Coll Med, Seoul, South Korea
[3] Yonsei Univ, Coll Med, Seoul, South Korea
来源：
CALCIFIED TISSUE INTERNATIONAL | 2004年 / 74卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S85 / S86
页数：2
相关论文
共 50 条
  • [21] Raloxifene therapy interacts with serum osteoprotegerin in postmenopausal women
    Messalli, Enrico M.
    Mainini, Giampaolo
    Scaffa, Cono
    Cafiero, Angela
    Salzillo, Pier Luigi
    Ragucci, Angelo
    Cobellis, Luigi
    MATURITAS, 2007, 56 (01) : 38 - 44
  • [22] Effect of bisphosphonate treatment on serum levels of osteoprotegerin and soluble RANK-ligand in patients with tumor-associated hypercalcemia
    Pohl, G
    Brenner, K
    Hawa, G
    Pecherstorfer, M
    BONE, 2004, 34 : S88 - S89
  • [23] Sequence variations in the osteoprotegerin gene promoter in patients with postmenopausal osteoporosis
    Arko, B
    Prezelj, J
    Komel, R
    Kocijancic, A
    Hudler, P
    Marc, J
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (09): : 4080 - 4084
  • [24] MicroRNA levels in bone and blood change during bisphosphonate and teriparatide therapy in an animal model of postmenopausal osteoporosis
    Kocijan, Roland
    Weigl, Moritz
    Skalicky, Susanna
    Geiger, Elisabeth
    Ferguson, James
    Leinfellner, Gabriele
    Heimel, Patrick
    Pietschmann, Peter
    Grillari, Johannes
    Redl, Heinz
    Hackl, Matthias
    BONE, 2020, 131
  • [25] Osteoprotegerin and RANKL serum levels in primary and secondary osteoporosis.
    Martini, C
    Salvadori, S
    Gennari, L
    Valenti, R
    Franci, B
    Campagna, S
    Avanzati, A
    Galli, B
    Merlotti, D
    Lucani, B
    Nuti, R
    JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 : S440 - S440
  • [26] Determinants of non-compliance with bisphosphonate therapy in women with postmenopausal osteoporosis
    van den Boogaard, C. H. A.
    Penning-Van Beest, F. J. A.
    Erkens, J. A.
    Engbersen, A. M. T.
    Herings, R. M. C.
    OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S167 - S168
  • [27] Calcium supply in women with postmenopausal osteoporosis on bisphosphonate therapy in daily practice
    Ringe, J. D.
    Moeller, G.
    Wick, B.
    OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S104 - S105
  • [28] Effect of concomitant statin therapy in bisphosphonate treated patients with osteoporosis.
    Guyer, JL
    Williams, MI
    Petkov, VI
    Adler, RA
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S400 - S400
  • [29] Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor κB in women with postmenopausal osteoporosis
    Reyes-Garcia, Rebeca
    Munoz-Torres, Manuel
    Fernandez Garcia, D.
    Mezquita-Raya, Pedro
    Garcia Salcedo, Jose Antonio
    de Dios Luna, Juan
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2010, 17 (01): : 140 - 144
  • [30] Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin
    Gatti, Davide
    Viapiana, Ombretta
    Adami, Silvano
    Idolazzi, Luca
    Fracassi, Elena
    Rossini, Maurizio
    BONE, 2012, 50 (03) : 739 - 742
12345